Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/16/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 4/16/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 4/16/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -0.62% | +0.50% | +33.92% | +60.07% | 64.38B | |
| +1.39% | +4.22% | +16.06% | +86.37% | 56.16B | |
| +0.94% | +2.15% | +15.58% | +107.19% | 54.16B | |
| -1.96% | -3.77% | +24.18% | +51.74% | 45.33B | |
| +0.43% | -1.85% | +20.25% | +98.62% | 42.25B | |
| -0.58% | +0.32% | +218.65% | +922.29% | 40.78B | |
| +3.01% | +45.76% | +109.51% | +93.57% | 33.8B | |
| -0.26% | -2.57% | +12.55% | +45.18% | 32.25B | |
| -1.29% | -2.88% | +21.60% | -11.92% | 23.57B | |
| Average | +0.13% | +4.34% | +52.48% | +161.46% | 43.63B | |
| Weighted average by Cap. | +0.17% | +3.36% | +49.44% | +160.40% |
Employees
51
